You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Nucala: Power to choose

Once-monthly dosing 1

Nucala is the only once-monthly* asthma biologic with a single fixed dose.**


Nucala is the only once-monthly* asthma biologic with a single fixed dose.** 1

Find out full posology information for Nucala.
See the SmPC


Nucala: The power to choose

The Nucala pre-filled pen or pre-filled syringe should be used for subcutaneous injection only. For administration in Hospitals only in Ireland. The injection can be given in the upper arm, thigh or abdomen. 1


The shelf-life of Nucala 100mg solution for injection in pre-filled pen and pre-filled syringe is 2 years.

Nucala pen and pre-filled syringe

  • Store in a refrigerator (2 – 8C)
  • Do not freeze
  • Store in the original carton in order to protect from light

If necessary, the pen and pre-filled syringe can be removed from the refrigerator and kept in the unopened pack for up to 7 days at room temperature (up to 30◦ C), when protected from light. The pack should be discarded if left out of the refrigerator for more than 7 days. The pen or pre-filled syringe must be administered within 8 hours once the pack is opened. The pack should be discarded if not administered within 8 hours.

Disposal 1
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Access more information on the storage and disposal of Nucala.
See the SmPC

SC, subcutaneous; SEA, severe eosinophilic asthma

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 1

*Every 4 weeks 1
**The recommended dose of Nucala 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as lyophilised powder. The licensed dose of Nucala in children aged 6 – 11 years is 40mg SC regardless of weight, and is available as a lyophilised powder


  1. Nucala Summary of Product Characteristics. Available from Last accessed: February 2020

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.